SCHEMBL4860223

SCHEMBL4860223

COc1ccccc1C(O)C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA12 O43570 1/20 0.50
CA4 P22748 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 2/20 0.49
CYP1A2 P05177 2/20 0.49
KDM4E B2RXH2 1/20 0.49
KMT2A Q03164 1/20 0.49
POLB P06746 2/20 0.47
HTT P42858 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ACHE P22303 1/20 0.45
CTSD P07339 1/20 0.44
ALDH1A1 P00352 1/20 0.44
AGTR1 P30556 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL306964 0.84 CA1 (0.54) CA1CA2CA12CA4CA7
SCHEMBL29386813 0.84 CA1 (0.54) CA1CA2CA12CA4CA7
SCHEMBL503435 0.82 KMT2A (0.55) CA1CA2CA12CA4CA7
SCHEMBL6400516 0.82 KMT2A (0.55) CA1CA2CA12CA4CA7
SCHEMBL503436 0.82 KMT2A (0.55) CA1CA2CA12CA4CA7
SCHEMBL13170107 0.82 POLB (0.49) CA1CA2CA12CA4CA7
SCHEMBL30402411 0.81 CYP3A4 (0.43) SMN1; SMN2LMNACYP1A2HTTACHE
SCHEMBL4554195 0.81 KMT2A (0.53) CA1CA2CA12CA4CA7
SCHEMBL7288497 0.81 CA1 (0.50) CA1CA2CA12CA4CA7
SCHEMBL9729192 0.81 KMT2A (0.53) CA1CA2CA12CA4CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363906-A2 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-11-26 EP claimed
WO-2002064586-A2 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-08-22 WO claimed
US-7361507-B1 Method for modulating nitrilase selectivity, nitrilases obtained by said method and use thereof AVENTIS ANIMAL NUTRITION S.A. (FR) 2008-04-22 US disclosed
EP-1228198-B1 METHOD FOR MODULATING NITRILASE SELECTIVITY, NITRILASES OBTAINED BY SAID METHOD AND USE THEREOF ADISSEO FRANCE SAS (FR) 2007-12-05 EP disclosed
EP-1363906-A2 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-11-26 EP disclosed
WO-2002064586-A2 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-08-22 WO disclosed
EP-1228198-A1 METHOD FOR MODULATING NITRILASE SELECTIVITY, NITRILASES OBTAINED BY SAID METHOD AND USE THEREOF AVENTIS ANIMAL NUTRITION S.A. (FR) 2002-08-07 EP disclosed
WO-2001034786-A1 METHOD FOR MODULATING NITRILASE SELECTIVITY, NITRILASES OBTAINED BY SAID METHOD AND USE THEREOF AVENTIS ANIMAL NUTRITION S.A. (FR) 2001-05-17 WO disclosed